f SGLT-2 Inhibitors as an Effective Treatment for Type 2 Diabetes Mellitus, Hypertension, and Hyperuricemia - A Mechanistic Perspective

References

1. SalvatoreT. GalieroR. CaturanoA. An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors.Int. J. Mol. Sci.2022237365110.3390/ijms23073651 35409011
   [Google Scholar]
2. Fonseca-CorreaJ.I. Correa-RotterR. Sodium-glucose cotransporter 2 inhibitors mechanisms of action: A review.Front. Med.2021877786110.3389/fmed.2021.777861 34988095
   [Google Scholar]
3. PereiraM.J. ErikssonJ.W. Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity.Drugs201979321923010.1007/s40265‑019‑1057‑0 30701480
   [Google Scholar]
4. SaishoY. SGLT2 inhibitors: The star in the treatment of type 2 Diabetes?Diseases2020821410.3390/diseases8020014 32403420
   [Google Scholar]
5. AnsaryT.M. NakanoD. NishiyamaA. Diuretic effects of sodium glucose cotransporter 2 inhibitors and their influence on the renin-angiotensin system.Int. J. Mol. Sci.201920362910.3390/ijms20030629 30717173
   [Google Scholar]
6. AdamC.A. AnghelR. MarcuD.T.M. MituO. RocaM. MituF. Impact of sodium–glucose cotransporter 2 (SGLT2) inhibitors on arterial stiffness and vascular aging—what do we know so far? (A narrative review).Life202212680310.3390/life12060803 35743834
   [Google Scholar]
7. HeratL.Y. MagnoA.L. RudnickaC. SGLT2 inhibitor–induced sympathoinhibition.JACC Basic Transl. Sci.20205216917910.1016/j.jacbts.2019.11.007 32140623
   [Google Scholar]
8. ChinoY. SamukawaY. SakaiS. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria.Biopharm. Drug Dispos.201435739140410.1002/bdd.1909 25044127
   [Google Scholar]
9. LaiS.W. HwangB.F. KuoY.H. LiuC.S. LiaoK.F. Sodium-glucose cotransporter-2 inhibitors use and the risk of gout: A systematic review and meta-analysis.Front. Endocrinol. (Lausanne)202314115815310.3389/fendo.2023.1158153 37288295
   [Google Scholar]
10. ZhangQ. ZhouS. LiuL. Efficacy and safety evaluation of SGLT2i on blood pressure control in patients with type 2 diabetes and hypertension: A new meta-analysis.Diabetol. Metab. Syndr.202315111810.1186/s13098‑023‑01092‑z 37280615
    [Google Scholar]
11. HalimiS. VergèsB. Adverse effects and safety of SGLT-2 inhibitors.Diabetes Metab.2014406Suppl. 1S28S3410.1016/S1262‑3636(14)72693‑X 25554069
    [Google Scholar]
12. ScheenA.J. SGLT2 inhibitors: Benefit/risk balance.Curr. Diab. Rep.201616109210.1007/s11892‑016‑0789‑4 27541294
    [Google Scholar]
13. MascoloA. Di NapoliR. BalzanoN. Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary.Front. Cardiovasc. Med.20229101069310.3389/fcvm.2022.1010693 36211584
    [Google Scholar]
14. UedaP. SvanströmH. MelbyeM. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: Nationwide register based cohort study.BMJ2018363k436510.1136/bmj.k4365 30429124
    [Google Scholar]
15. PittampalliS. UpadyayulaS. MekalaH.M. LippmannS. Risks vs benefits for SGLT2 inhibitor medications.Fed. Pract.20183574548 30766374
    [Google Scholar]
16. MatthewsJ. HeratL. SchlaichM.P. MatthewsV. The impact of SGLT2 inhibitors in the heart and kidneys regardless of diabetes status.Int. J. Mol. Sci.202324181424310.3390/ijms241814243 37762542
    [Google Scholar]
17. CarusoI. GiorginoF. SGLT-2 inhibitors as cardio-renal protective agents.Metabolism202212715493710.1016/j.metabol.2021.154937 34808144
    [Google Scholar]
18. GrondaE. LopaschukG.D. ArduiniA. Mechanisms of action of SGLT2 inhibitors and their beneficial effects on the cardiorenal axis.Can. J. Physiol. Pharmacol.202210029310610.1139/cjpp‑2021‑0399 35112597
    [Google Scholar]